In this issue

Issue 102 • January 2021

There have been two top stories dominating headlines over the past few months: Covid-19 and the US election. Both topics will have significant global reverberations around the world over the coming years, a fact made quite clear when healthcare was certified as a key political issue during the pre-election debates. After Joe Biden was officially declared President-elect, attentions turned to how his potential policies may affect different industries – notably how his new administration would deal with the pharma industry during a period of heightened demand on the sector.

With this in mind, we take a close look at Biden’s previous attitude towards Big Pharma to find out what the industry can expect from the incoming administration.

Elsewhere in this issue, we investigate the ethical implications of developing a drug to targets one of the most common types of dwarfism, learn what it takes to fast track a vaccine from concept to delivery, and track the ground-breaking discovery of Hepatitis C that landed three scientists the 2020 Nobel Prize for Medicine.

Plus, we find out why anti-counterfeit packaging is becoming a hot topic in Brexit discussions, explore the growing trend of self-medication, and ask if the pharma industry’s sustainability goals are bold enough.

All this and more in this latest issue of Pharma Technology Magazine.

Eloise Mclennan, editor

Go to article: Home | Is Joe Biden good news for US pharma?Go to article: In this issueGo to article: ContentsGo to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: CommentGo to article: Pipeline agents in the RA marketGo to article: US seeing alarming increases in Covid-19 casesGo to article: IDMP: Where are we now and what lies ahead?Go to article: The rising role of the microbiomeGo to article: What the pandemic highlights about IDMP’s potentialGo to article: In DepthGo to article: Solving the puzzle of Hepatitis CGo to article: Why is President-elect Joe Biden a good pick for the pharma industry?Go to article: Is self-medication the future of pharma?Go to article: Restricted growth: Challenging attitudes to achondroplasiaGo to article: How do you fast-track a vaccine? UCL scientists weigh in Go to article: Fraudulent pharmaceuticals: the legacy of anti-counterfeit packagingGo to article: Are healthcare’s sustainability goals bold enough?Go to article: New Zealand: a promising destination for trials in a post-Covid-19 world?Go to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue